Last updated: September 13, 2026
Fezolinetant, marketed in the United States as Veoza and in some markets as Veoza or Veoza-related brand names, is Astellas Pharma’s nonhormonal neurokinin 3 receptor antagonist for moderate-to-severe vasomotor symptoms associated with menopause. The drug entered the U.S. market in 2023 and has become Astellas’ principal commercial opportunity in women’s health.
The investment case depends on three variables: adoption among women who cannot or do not want to use hormone therapy, durability of reimbursement at a premium branded price, and the timing of generic or competing NK3-antagonist entry. Astellas has a differentiated mechanism and a large untreated population, but commercial uptake faces liver-monitoring requirements, payer controls, patient awareness constraints, and competition from low-cost generic therapies.
What is fezolinetant and how does Veoza work?
Fezolinetant is an oral, selective neurokinin 3 receptor antagonist. It blocks neurokinin B signaling in the hypothalamic thermoregulatory center, which is implicated in menopausal hot flashes and night sweats.
The FDA approved Veoza on May 12, 2023, for moderate-to-severe vasomotor symptoms due to menopause. It is not an estrogen product and does not carry the same estrogen-related treatment profile as menopausal hormone therapy. The recommended dose is 45 mg once daily, with or without food. [1]
| Attribute |
Fezolinetant / Veoza |
| Active ingredient |
Fezolinetant |
| Mechanism |
Selective neurokinin 3 receptor antagonist |
| Initial U.S. approval |
May 12, 2023 |
| Indication |
Moderate-to-severe vasomotor symptoms associated with menopause |
| Dose |
45 mg orally once daily |
| U.S. sponsor |
Astellas Pharma US, Inc. |
| Drug class |
Nonhormonal menopause therapy |
| Key clinical competitors |
Hormone therapy, SSRIs, SNRIs, gabapentin, oxybutynin, emerging NK3 antagonists |
| Key safety issue |
Drug-induced liver injury and hepatic monitoring |
Clinical studies showed reductions in the frequency and severity of hot flashes compared with placebo. The product’s commercial differentiation is its targeted mechanism and nonhormonal status rather than a materially lower price or a simpler monitoring profile. [1]
What is the FDA regulatory status of fezolinetant?
Veoza has full FDA approval for menopausal vasomotor symptoms. The FDA label requires hepatic laboratory testing before treatment and during therapy because of potential liver injury.
The monitoring requirements have become a central commercial issue. The prescribing information requires liver testing before initiation, monthly during the first three months, and at specified later intervals. Testing is also required when symptoms suggest liver injury. Patients with cirrhosis or certain hepatic conditions are excluded or restricted under the label. [2]
In 2024, the FDA updated the product’s safety information after postmarketing reports and clinical-trial data raised concerns about elevated liver enzymes and rare serious liver injury. The revised safety information increases the operational burden for prescribers and patients, although it does not remove Veoza from the market. [2]
International regulatory position
The European Commission authorized fezolinetant in December 2023 for moderate-to-severe vasomotor symptoms associated with menopause. European regulators also require liver-function monitoring and restrictions involving hepatic impairment. [3]
Regulatory status varies by country because reimbursement, prescribing restrictions, and the availability of hormone therapy differ. Astellas has pursued a broad commercial launch across Europe, but U.S. revenue remains the most important near-term contributor because of the size of the branded prescription market and higher launch pricing.
How large is the market for fezolinetant?
The addressable market is large, but the commercially reachable population is narrower.
Most menopausal women experience vasomotor symptoms at some point. A smaller subset experiences symptoms severe enough to seek medical treatment. The target population is further reduced by:
- Patients who prefer or tolerate hormone therapy.
- Patients who use low-cost generic nonhormonal drugs.
- Patients who do not consult a clinician.
- Patients unable to access or afford branded therapy.
- Patients with liver disease or other contraindications.
- Payers requiring prior authorization or step therapy.
The strongest target segment is women with moderate-to-severe symptoms who cannot use hormone therapy, do not want hormone therapy, or remain inadequately controlled on existing nonhormonal treatments. The drug also has potential among patients and physicians seeking a menopause-specific therapy rather than an antidepressant or anticonvulsant used off label.
Competitive treatment landscape
| Treatment category |
Examples |
Commercial advantage |
Limitation |
| Menopausal hormone therapy |
Estradiol, conjugated estrogens, combination products |
Strong efficacy and broad clinical experience |
Not appropriate or preferred for all patients |
| SSRIs/SNRIs |
Paroxetine, venlafaxine, escitalopram |
Low cost and familiar prescribing |
Off-label or less targeted use; tolerability issues |
| Gabapentin |
Generic gabapentin |
Low cost |
Sedation and neurologic adverse effects |
| Oxybutynin |
Generic oxybutynin |
Low cost and nonhormonal |
Anticholinergic adverse effects |
| Fezolinetant |
Veoza |
Targeted, nonhormonal mechanism |
Branded price and liver monitoring |
| Emerging NK3 antagonists |
Elinzanetant and other pipeline programs |
Potential class competition |
Regulatory and commercial timing remain decisive |
Fezolinetant’s best commercial argument is not that it replaces all menopause therapies. It occupies a specific position between hormone therapy and inexpensive off-label nonhormonal medicines.
What has been the financial trajectory for Veoza?
Astellas has identified fezolinetant as a growth product within its strategic plan, alongside oncology and immunology assets. Early sales were limited by the U.S. launch ramp, payer access, physician education, and the time required to establish menopause treatment pathways.
Astellas’ fiscal-year reporting places Veoza among its newer products with material growth expectations. Reported sales increased from an initial launch base in fiscal 2023, with management targeting continued expansion through broader geographic commercialization and increased diagnosis and treatment of vasomotor symptoms. [4]
Because Astellas reports primarily in Japanese yen and product-level disclosures can vary by fiscal period, the most useful financial interpretation is directional:
| Financial factor |
Effect on Veoza trajectory |
| U.S. launch in 2023 |
Created an early revenue base but required a specialty-market ramp |
| European launches |
Expanded geographic reach and reduced dependence on the U.S. |
| Premium branded pricing |
Supports revenue per treated patient |
| Insurance restrictions |
Slows prescription conversion and may increase abandonment |
| Liver monitoring |
Adds clinical friction and administrative cost |
| Large untreated population |
Provides long-term volume upside |
| Generic alternatives |
Limits achievable net price |
| New NK3 competitors |
Could compress share and payer leverage |
Astellas has not disclosed Veoza revenue at a level that permits a stand-alone public valuation with the precision available for larger products. The drug’s financial importance is therefore better assessed through prescription growth, geographic rollout, reimbursement expansion, and its contribution to the company’s growth-product portfolio.
Revenue exposure and commercial sensitivity
Veoza’s revenue is sensitive to four operating metrics:
- New-patient starts.
- Persistence after the first prescription.
- Net price after rebates and patient support.
- The proportion of patients obtaining coverage without prior authorization.
The product has meaningful operating leverage because the active pharmaceutical ingredient is a small-molecule oral drug. Manufacturing costs should represent a modest portion of gross sales relative to commercial, medical-affairs, market-access, and patient-support expenses. The principal near-term cost risk is not manufacturing capacity. It is the cost of building a new therapeutic category and managing liver-safety monitoring.
What patents protect fezolinetant and Veoza?
Fezolinetant is protected by Astellas patent families covering the active compound, pharmaceutical compositions, medical use, and potentially solid-state or formulation aspects. U.S. patent records identify Astellas-related patents covering substituted benzamide compounds and associated therapeutic uses. [5]
The core U.S. composition-of-matter protection is generally expected to provide the principal barrier to generic entry through approximately 2030, subject to patent-term adjustment, patent-term extension, claim scope, and the specific Orange Book listing. Later-expiring patents may cover formulations, dosage forms, or methods of treating menopausal vasomotor symptoms.
Public patent databases and FDA Orange Book records should be read together because the relevant generic-entry date depends on the patents listed for the approved product, not merely on the earliest compound patent in the family. [5][6]
Patent estate by protection category
| Protection category |
Commercial purpose |
Generic-entry relevance |
| Composition of matter |
Protects fezolinetant chemical structure |
Usually the strongest barrier |
| Pharmaceutical composition |
Covers drug-containing formulations |
Can delay or complicate design-around strategies |
| Method of treatment |
Covers use for menopausal vasomotor symptoms |
Relevant to label-based generic competition |
| Solid-state or process claims |
Protect crystal forms or manufacturing routes |
Can raise technical and litigation risk |
| Regulatory exclusivity |
Protects FDA approval data for a limited period |
Separate from patent expiration |
The strength of the estate is highest if the core compound claims remain valid and enforceable. Formulation and method-of-use patents are commercially useful but generally more vulnerable to validity, claim-construction, or non-infringement challenges than a well-supported composition-of-matter patent.
When does fezolinetant lose exclusivity?
The principal U.S. patent barrier is expected to remain in place into the early 2030s, with the core composition patent commonly associated with an expiration around 2030. The actual generic launch date may occur later if additional listed patents survive litigation or if pediatric or patent-term adjustments apply.
| Exclusivity element |
Expected timing or status |
| U.S. FDA approval |
May 2023 |
| New chemical entity exclusivity |
Five years from approval, subject to Paragraph IV timing rules |
| Core patent protection |
Approximately 2030 for the principal compound family |
| Potential later patents |
May extend into the 2030s depending on listed claims |
| First generic opportunity |
Dependent on ANDA filing, Paragraph IV certification, litigation, and settlement |
| Biosimilar pathway |
Not applicable; fezolinetant is a small molecule |
New chemical entity exclusivity initially prevented an ANDA based on the full approval application from being submitted for five years, except for a Paragraph IV patent challenge during the final year. [6] Once patent and regulatory barriers decline, generic competition could emerge quickly because the product is an oral small molecule rather than a biologic.
Are there Paragraph IV challenges or generic lawsuits against Veoza?
No publicly reported Paragraph IV litigation or major ANDA challenge against Veoza had materially altered the U.S. market position through mid-2025. That does not eliminate future litigation risk. Generic companies can file challenges near the end of regulatory exclusivity, and a public case may not appear until an ANDA notice triggers litigation.
The most likely litigation issues are:
- Validity of the core compound patent.
- Infringement of composition or method-of-use claims.
- Orange Book listing disputes.
- Whether a proposed generic label would induce infringement.
- The scope of any formulation or solid-state claims.
- Settlement timing and launch dates.
Generic launch scenarios
| Scenario |
Likely effect |
| Core compound patent upheld through approximately 2030 |
Brand retains substantial protection |
| Early Paragraph IV settlement |
Generic launch may occur before nominal patent expiry |
| Core patent invalidated |
Rapid price erosion and accelerated substitution |
| Only method-of-use patents remain |
Skinny-label generic entry becomes more plausible |
| Multiple generic entrants after expiry |
Fast net-price erosion and significant share loss |
| Competing branded NK3 antagonist launches first |
Earlier payer pressure without immediate generic substitution |
A generic launch could reduce price materially because the molecule is orally administered and relatively straightforward to manufacture. The commercial erosion would depend on the number of entrants, pharmacy substitution rules, and whether the branded product retains an indication-specific or service-based advantage.
What is the Orange Book status of Veoza?
Veoza’s Orange Book position is determined by the patents that Astellas has listed for the approved product and indication. The relevant analysis must distinguish between:
- Patents listed against the drug substance.
- Patents listed against the drug product or formulation.
- Method-of-use patents.
- Patent expiration dates.
- Any patent-term extension or adjustment.
- Whether a patent is eligible for an ANDA Paragraph IV challenge.
The FDA Orange Book is the controlling public source for listed patents and exclusivity information. Patent databases alone cannot establish the current regulatory barrier. [6]
A business assessment should therefore use the current Orange Book entry, FDA patent listing updates, and the latest Astellas litigation disclosures rather than relying only on a family-level patent expiration date.
How strong is the fezolinetant patent estate?
The estate appears commercially meaningful because it combines a protected new chemical entity with use-specific coverage for a defined menopausal indication. Its strength is greater than that of a product relying only on a method-of-use patent.
The main vulnerabilities are predictable for a small-molecule pharmaceutical:
- Prior-art attacks against compound claims.
- Obviousness challenges based on known NK3 antagonists.
- Written-description and enablement challenges.
- Non-infringement arguments involving generic labels.
- Patent-term differences across jurisdictions.
- Weakness in later-filed formulation claims.
The estate is strongest in the United States if the core composition patent remains enforceable. European protection depends on national validation and litigation outcomes, while emerging-market protection can be materially shorter or less enforceable.
Which companies are challenging or competing with Astellas?
The most immediate competition comes from low-cost generic drugs used off label, hormone therapy, and other branded menopause products. Bayer’s elinzanetant is the most visible potential branded pharmacologic competitor in the NK3 or neurokinin pathway. Bayer has advanced elinzanetant through late-stage development and regulatory filings, creating a potential future head-to-head commercial challenge. [7]
Competitive pressure may arise before any competitor demonstrates superior efficacy. Payers can use a second branded NK3 antagonist to negotiate rebates, impose preferred-product status, or require step therapy.
Astellas’ strategic defenses include expanding prescriber familiarity, maintaining favorable reimbursement, generating longer-term safety and persistence data, and broadening the evidence base across menopause-related symptom burdens.
What licensing deals affect fezolinetant?
Fezolinetant originated from Astellas’ internal research and is commercialized globally by Astellas. No major third-party licensing transaction has been central to the product’s public commercial profile through mid-2025.
The absence of a prominent external license means Astellas retains substantial control over pricing, development, regulatory sequencing, and geographic commercialization. It also retains most of the launch and postmarketing obligations.
What manufacturing and intellectual-property barriers exist?
Fezolinetant is a synthetic small molecule, so it does not face the cell-line, cold-chain, or complex biologic manufacturing barriers associated with monoclonal antibodies. The main manufacturing protections are likely to involve chemical-process know-how, impurity control, polymorphism, scale-up, and quality specifications.
Manufacturing is unlikely to be the primary constraint on generic entry. Patent validity, regulatory timing, and commercial substitution are more important. A generic company that avoids protected processes may still be able to manufacture an equivalent active ingredient through an independent route.
What geographic markets matter most for fezolinetant?
The United States is the primary commercial market because of its large branded pharmaceutical opportunity and relatively high prescription pricing. Europe provides geographic diversification but usually has stronger price negotiation and country-specific reimbursement controls.
| Region |
Market implication |
| United States |
Largest near-term revenue opportunity; higher access and litigation value |
| European Union |
Broad regulatory reach but greater price and reimbursement pressure |
| United Kingdom |
National reimbursement assessment is important for uptake |
| Japan |
Strategic importance for Astellas, but local menopause prescribing dynamics differ |
| Emerging markets |
Volume potential, lower pricing, and variable patent enforcement |
Patent expiry and generic entry will not occur uniformly worldwide. Astellas may retain exclusivity in some countries after launch of generic products elsewhere because national patent terms, regulatory approvals, and litigation differ.
What is the investment outlook for Veoza?
Veoza has a credible growth profile but requires sustained execution. The product addresses a large and under-treated condition, has a differentiated nonhormonal mechanism, and benefits from Astellas’ global commercial infrastructure.
The principal upside drivers are:
- Increased diagnosis of menopausal vasomotor symptoms.
- Greater acceptance of prescription menopause treatment.
- Use in women who avoid hormone therapy.
- Expansion of insurance coverage.
- Strong persistence after initiation.
- Successful launch in Europe and other markets.
- Limited near-term branded competition.
The principal downside risks are:
- Liver-safety monitoring and treatment discontinuation.
- Low-cost generic and off-label alternatives.
- Patient copay and reimbursement friction.
- Slower-than-expected physician adoption.
- New branded NK3 competitors.
- Patent challenges before the expected 2030 core patent horizon.
- Long-term safety findings that narrow the label or target population.
The asset should be valued as a growing branded specialty product with meaningful pre-generic runway, not as a permanent franchise. Its long-term revenue ceiling depends on whether Astellas can convert menopause treatment from episodic symptom management into sustained prescription use.
Key Takeaways
- Fezolinetant is Astellas’ nonhormonal NK3 receptor antagonist for menopausal vasomotor symptoms.
- Veoza received FDA approval in May 2023 and has expanded into European markets.
- Its main commercial advantage is a targeted nonhormonal mechanism for women who cannot or do not want to use hormone therapy.
- Liver-function monitoring is the central safety and adoption constraint.
- The core U.S. patent barrier is expected to extend to approximately 2030, with later patent claims potentially affecting generic timing.
- No major publicly reported Paragraph IV litigation had materially changed the market position through mid-2025.
- Generic entry would likely produce rapid price erosion because fezolinetant is an oral small molecule.
- Bayer’s elinzanetant represents the most important potential branded pharmacologic competitor.
- Astellas’ financial upside depends on prescription growth, persistence, reimbursement, and international commercialization.
- The product has meaningful growth potential but remains exposed to payer friction, safety monitoring, and future competition.
FAQs
Is fezolinetant a hormone replacement therapy?
No. Fezolinetant is a nonhormonal neurokinin 3 receptor antagonist. It does not supply estrogen or progestogen.
Can fezolinetant be used by women with liver disease?
Use is restricted by the FDA label in patients with significant hepatic impairment and requires liver-function testing. The drug is not appropriate for every patient with liver disease. [2]
Is Veoza covered by Medicare?
Coverage varies by Medicare Part D plan, formulary tier, prior-authorization rules, and the patient’s clinical circumstances. Coverage is not uniform across plans.
Will generic fezolinetant be available soon?
A near-term generic launch was not established through mid-2025. The main U.S. patent barrier is expected to extend to approximately 2030, although a Paragraph IV challenge or settlement could change the timing.
Does fezolinetant have biosimilar competition?
No. Fezolinetant is a synthetic small molecule, so competition would occur through the generic-drug pathway rather than the biosimilar pathway.
References
- U.S. Food and Drug Administration. (2023). FDA approves Veoza for moderate to severe vasomotor symptoms due to menopause.
- U.S. Food and Drug Administration. (2024). Veoza (fezolinetant) prescribing information.
- European Medicines Agency. (2023). Veoza: EPAR product information.
- Astellas Pharma Inc. (2024-2025). Financial results materials and corporate strategic plan.
- U.S. Patent and Trademark Office. (2025). Patent records for fezolinetant and related Astellas patent families.
- U.S. Food and Drug Administration. (2025). Approved Drug Products with Therapeutic Equivalence Evaluations, Orange Book.
- Bayer AG. (2024-2025). Elinzanetant clinical development and regulatory communications.
